Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

Inclusion criteria

• Male and female patients 18 to 65 years of age with clinically diagnosed chronic HS for at least 1 year (prior to screening) who have undergone previous antibiotic therapy
• Weight between 50 kg and 150 kg
• HS-PGA score of at least moderate severity at the time of inclusion with at least 4 abscesses and/or nodules. HS lesions must be present in at least two distinct anatomical areas, and at least one area must be minimally Hurley Stage II (moderate)

Exclusion criteria

• Use of previous biologics or other specified concomitant medications
• Use of any systemic treatment for HS in the last 4 weeks prior to randomization
• Presence of more than 25 draining fistulae.
• Surgical treatment for HS in the last 4 weeks prior to randomization/first treatment.
• Women of child-bearing potential and sexually active males unwilling to use a condom during intercourse while taking drug and for 15 weeks after stopping investigational medication.
• Evidence of active tuberculosis at screening
• History of severe systemic Candida infections or evidence of Candidiasis in the last two weeks
• Active systemic or skin infections (other than common cold or HS related) during the two weeks before randomization/first treatment
• Any live vaccines (including nasal spray flu vaccine) starting from 6 weeks before randomization.

Other protocol-defined inclusion/exclusion criteria may apply